India's central drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has taken significant steps to enhance oversight of the marketing practices surrounding GLP-1 receptor agonists, which are prescribed for obesity and metabolic disorders. Following a meeting of the Drugs Consultative Committee (DCC) on March 20, the CDSCO issued an advisory against misleading promotions for these prescription-only drugs. State drug controllers are now tasked with monitoring compliance with approved indications and ethical marketing practices, with the authority to enforce actions against violations. The Indian Pharmacopoeia Commission (IPC) will conduct monthly reviews of adverse events related to these medications. The urgency for these measures comes as Indian pharmaceutical companies have launched over 50 generic brands of semaglutide, the active ingredient in popular obesity drugs like Ozempic and Wegovy, following the expiration of key patents. This has led to a dramatic price drop of over 90%. The DCC's recommendations emphasize the need to protect vulnerable populations from being exploited by misleading marketing tactics, particularly in a landscape where celebrity endorsements and social media influence have significantly shaped consumer interest in these drugs.